PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023 is a new market research publication announced by Reportstack. Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

It was estimated that prescription drug sales for IBS in the US were approximately $480.1m in 2013. The key growth drivers for the IBS market in the US are the anticipated increasing uptake of Ironwood/Actavis/Almirall/Astellas’ Linzess, the potential label expansion of Salix/Alfa Wassermann/Norgine/Bama-Geve’s Xifaxan for IBS-D, the potential introduction of four additional therapies, and the increasing prevalent cases of IBS during the forecast period.

To view the table of contents and know more details please visit PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023.


- Overview of Irritable Bowel Syndrome including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Irritable Bowel Syndrome market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Irritable Bowel Syndrome
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in the US

About Reportstack:

Reportstack  is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack  members with cutting edge research products to facilitate strategic business decisions.


Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research